CAM
IMVT icon

Concorde Asset Management’s Immunovant IMVT Stock Holding History

Concorde Asset Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-16,725
Closed -$297K – 114
2022
Q4 		$297K Buy
+16,725
New +$211K 0.26% 94

Other funds holding IMVT

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Concorde Asset Management's IMVT Position: Q1 2023 in Review

Concorde Asset Management sold out of Immunovant (IMVT) in Q1 2023, closing a stake of 16,725 shares — an estimated $297K sold.

Concorde Asset Management first reported a position in IMVT in Q4 2022 and held it in 1 quarter. The position peaked at $297K in Q4 2022. 142 funds tracked by Wall St. Rank hold IMVT as of Q1 2023.

  • Concorde Asset Management reported no remaining Immunovant position as of Q1 2023 after selling out during the quarter.
  • Concorde Asset Management sold 16,725 Immunovant shares in Q1 2023, an estimated $297K.
  • Concorde Asset Management first reported a position in Immunovant in Q4 2022 and held it in 1 quarter.
  • Concorde Asset Management's Immunovant position peaked at $297K in Q4 2022.
  • 142 funds tracked by Wall St. Rank held Immunovant as of Q1 2023.

Based on Concorde Asset Management's 13F filing for Q1 2023, filed 9 May 2023.